World Osteoporosis Drugs Market - Opportunities and Forecasts, 2017-2023

Pharmaceuticals	LI_181491	Pages: NA	May 2018 \| 513 Views
Author's : NA	Tables: NA	Charts: NA	Formats*:

Osteoporosis is a condition in which the bones become weak and fragile due to the loss of tissue. This condition can arise due to hormonal changes, the deficiency of calcium or vitamin. In osteoporosis, the microstructure of bones is changed due to the change in bone mass and bone density. Osteoporosis can cause severe injury or pain and requires timely treatment. Osteoporosis patients find it difficult to comply with the strict dosage schedules of drugs, hence the drug developers are focusing on the production of osteoporosis drugs with easy dosage patterns. The increasing incidences of osteoporosis, a considerable rise in the geriatric populations along with a large prevalence of sedentary lifestyles, would supplement the developments and growth in the global osteoporosis drugs market over the analysis period. The use of RANK Ligand Inhibitors to treat osteoporosis has created opportunities for new as well as existing players, to develop new drugs in the market. Factors restraining the market growth are stringent regulatory environment and the time consuming drug approval process.

The global osteoporosis market, is segmented on the basis of Drug Type, Application and Geography. The drug types considered, in this report include Parathyroid Hormone Therapy (PTH) Drugs, Bisphosphonates, Calcitonin, Selective Estrogen Receptor Modulators (SERMs), RANKL (Receptor activator of nuclear factor kappa-B ligand) Inhibitors and Others (Vitamin D, Calcium). Based on applications the market is classified into Primary Type 1 Osteoporosis, Primary Type 2 Osteoporosis and Secondary Osteoporosis. Geographically, the market is segmented across four regions namely North America, Europe, Asia Pacific and LAMEA. One of the strategies adopted by major market players is product launch. For instance, recently in 2015, Eli Lilly has launched a product named teriparatide, a new drug for osteoporosis. This drug, which can be self-injected is being delivered to patients houses directly without middlemen ship of pharmacies, which has helped company to earn additional margins. The companies profiled in this report are Aegis therapeutics, Amgen, Bone medical, Chugai pharmaceutical, Eli lilly, Merck & co., Novartis pharma, Novo nordisk, Ranbaxy laboratories and Osteologix.

KEY MARKET BENEFITS:

The report provides a quantitative analysis of the current market and estimations through 2014-2020, which would enable the stakeholders to capitalize on prevailing market opportunities
Extensive analysis of the global Osteoporosis Drugs market by product type helps in understanding the types of equipment that are currently used along with the variants that would gain prominence in future
Competitive intelligence highlights the business practices followed by leading market players across various geographies
Comprehensive analysis of factors that drive and restrict the growth of the global Osteoporosis Drugs market is provided
SWOT analysis highlights the internal environment of leading companies for effective strategy formulation
The Osteoporosis Drugs market scenario is comprehensively analysed in accordance to the key regions

KEY MARKET SEGMENTS:

The Osteoporosis Drugs Market is segmented as below:

Osteoporosis Drugs Market By Drug Type

Parathyroid Hormone Therapy (PTH) Drugs
Bisphosphonates
Calcitonin
Selective Estrogen Receptor Modulators (SERMs)
RANKL (Receptor activator of nuclear factor kappa-B ligand) Inhibitors
Others (Vitamin D, Calcium)

Osteoporosis Drugs Market By Application

Primary Type 1 Osteoporosis
Primary Type 2 Osteoporosis
Secondary Osteoporosis

Osteoporosis DrugsMarket By Geography

North America
Europe
Asia Pacific
LAMEA

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
Technologically sophisticated and reliable insights through well audited and veracious research methodology
Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

Patent and regulatory databases for understanding of technical & legal developments
Scientific and technical writings for product information and related preemptions
Regional government and statistical databases for macro analysis
Authentic new articles, web-casts and other related releases for market evaluation
Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

Validates and improves the data quality and strengthens research proceeds
Further develops analyst team’s market understanding and expertise
Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

Chief executives and VPs of leading corporations specific to industry
Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.